EFFECT OF LB 46, A NEW BETA-ADRENERGIC ANTAGONIST, IN HYPERTHYROIDISM
| Autor: | Lars Runeberg, K.‐E. Kreus |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Tachycardia medicine.medical_specialty Indoles Adrenergic beta-Antagonists Physical Exertion Administration Oral Blood Pressure Placebo Hyperthyroidism Placebos Heart Rate Oral administration Internal medicine Heart rate Internal Medicine medicine Humans Rest (music) Beta-adrenergic blocking agent business.industry Antagonist Blood pressure Endocrinology Sympatholytics Cardiology Female medicine.symptom business |
| Zdroj: | Acta Medica Scandinavica. 189:423-426 |
| ISSN: | 0001-6101 |
| DOI: | 10.1111/j.0954-6820.1971.tb04400.x |
| Popis: | The effect of oral administration of a single dose of 5 mg (6 patients) and 10 mg (6 patients) of LB 46 (Sandoz Ltd., Basel), a new β-adrenergic antagonist, or placebo (3 patients), on the heart rate and blood pressure at rest and during exercise on a bicycle ergometer has been studied in patients with untreated hyperthyroidism. The two doses had essentially similar effects and decreased the heart rate by about 20% both at rest and during work. There was a marked increase in the calculated physical working capacity at 170 heart beats/min (PWC170) but no significant change in the actual physical working capacity. There was a slight but statistically insignificant decrease in blood pressure. Five mg of LB 46 was given every 8 h for 1 to 3 weeks without any other medication, and the exercise test was then repeated with essentially similar results. Two patients developed transient disturbances of cardiac rhythm during ergometry after 10 mg of LB 46, but all the patients did well during the subsequent continuous administration of the drug. It is concluded that LB 46 is effective in decreasing tachycardia in hyperthyroidism and, mainly in this way, it increases the PWC170. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|